Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

J Nucl Cardiol. 2019 Aug;26(4):1125-1134. doi: 10.1007/s12350-018-1298-4. Epub 2018 May 14.

Abstract

Coronary microvascular dysfunction and, its functional consequence, myocardial ischemia are common pathologic features in patients with hypertrophic cardiomyopathy (HCM). Both have been commonly invoked as potential triggers of and/or contributors to the underlying pathophysiological processes leading to heart failure, and malignant ventricular arrhythmias. Positron emission tomography (PET) with myocardial blood flow quantification provides a unique opportunity to evaluate the integrity and function of the coronary microcirculation in HCM. The purpose of the present review is to summarize all the pertinent literature and future perspectives of the role of PET in the evaluation and risk stratification of patients with HCM.

Keywords: Basic science; Diseases/processes; Modalities; Tests.

Publication types

  • Review

MeSH terms

  • Cardiomyopathy, Hypertrophic / diagnostic imaging*
  • Chest Pain
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Circulation
  • Heart / diagnostic imaging*
  • Heart Failure
  • Humans
  • Microcirculation
  • Myocardial Ischemia / diagnostic imaging
  • Positron-Emission Tomography*
  • Risk Assessment
  • Tomography, Emission-Computed, Single-Photon